Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Long-Term Investments (2016 - 2022)

Assembly Biosciences (ASMB) has 6 years of Long-Term Investments data on record, last reported at $11.7 million in Q4 2022.

  • For Q4 2022, Long-Term Investments fell 58.02% year-over-year to $11.7 million; the TTM value through Dec 2022 reached $11.7 million, down 58.02%, while the annual FY2022 figure was $11.7 million, 58.02% down from the prior year.
  • Long-Term Investments reached $11.7 million in Q4 2022 per ASMB's latest filing, down from $11.9 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $28.0 million in Q4 2021 and bottomed at $2.2 million in Q2 2018.
  • Average Long-Term Investments over 3 years is $13.5 million, with a median of $11.8 million recorded in 2022.
  • Peak YoY movement for Long-Term Investments: fell 26.75% in 2018, then tumbled 58.02% in 2022.
  • A 3-year view of Long-Term Investments shows it stood at $2.2 million in 2018, then surged by 1169.09% to $28.0 million in 2021, then crashed by 58.02% to $11.7 million in 2022.
  • Per Business Quant database, its latest 3 readings for Long-Term Investments were $11.7 million in Q4 2022, $11.9 million in Q2 2022, and $28.0 million in Q4 2021.